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Abstract
The current pandemic emergence of novel coronavirus disease (COVID-19) poses a rele-
vant threat to global health. SARS-CoV-2 infection is characterized by a wide range of clini-
cal manifestations, ranging from absence of symptoms to severe forms that need intensive
care treatment. Here, plasma-EDTA samples of 30 patients compared with age- and sex-
matched controls were analyzed via untargeted nuclear magnetic resonance (NMR)-based
metabolomics and lipidomics. With the same approach, the effect of tocilizumab administra-
tion was evaluated in a subset of patients. Despite the heterogeneity of the clinical symp-
toms, COVID-19 patients are characterized by common plasma metabolomic and lipidomic
signatures (91.7% and 87.5% accuracy, respectively, when compared to controls). Tocilizu-
mab treatment resulted in at least partial reversion of the metabolic alterations due to
SARS-CoV-2 infection. In conclusion, NMR-based metabolomic and lipidomic profiling pro-
vides novel insights into the pathophysiological mechanism of human response to SARS-
CoV-2 infection and to monitor treatment outcomes.
Author summary
The current COVID-19 pandemic caused by severe acute respiratory syndrome coronavi-
rus-2 (SARS-CoV-2) is markedly affecting the world population. Here we report about
the small-molecule profile of patients hospitalized during the first wave of the COVID-19
pandemic in Florence (Italy). Using magnetic resonance spectroscopy, we showed that the
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infection induces profound changes in the metabolome. The analysis of the specific
metabolite changes and correlations with clinical data enabled the identification of poten-
tial biochemical determinants of the disease fingerprint. We also followed how metabolic
alterations revert towards those of the control group upon treatment with tocilizumab, a
recombinant humanized monoclonal antibody against the interleukin-6 receptor. These
results open up possibilities for the monitoring of novel patients and their individual
response to treatment.
Introduction
The World Health Organization announced coronavirus disease 2019 (COVID-19) outbreak a
pandemic in March 2020 [1,2]. At the beginning of October 2020 over thirty-four millions of
patients have been diagnosed by SARS-CoV-2 infection and about 1 million deaths are
reported all over the world [3]. The SARS-CoV-2 infection is characterized by a wide range of
clinical manifestations, ranging from absence of symptoms to severe forms that need intensive
care treatment. About 20% of patients, particularly the older ones and those affected by
chronic comorbidities such as hypertension, diabetes mellitus, renal and heart diseases, may
develop interstitial pneumonia and respiratory distress requiring oxygen therapy or mechani-
cal ventilation [4]. In addition to interstitial pneumonia and acute respiratory distress syn-
drome (ARDS), COVID-19 is associated with other life-threatening complications such as
sepsis, thromboembolism and multi-organ failure [5]. Patients with the highest rate of morbid-
ity and mortality following SARS-CoV-2 infection develop a hyperinflammatory syndrome
due to the overproduction of early response proinflammatory cytokines (such as IL-1β, IL-6,
TNFα, MCP-1)–the so called “cytokine storm”–leading to an increased vascular permeability,
activation of coagulation pathways, dysregulation of T cells with associated lymphopenia, mul-
tiorgan injury and rapid clinical deterioration [6–9].
Metabolomics and lipidomics can contribute a system level picture, thus expanding the
options that chemists can explore to help fight the pandemic [10]. The human metabolome is
composed by an ensemble of several thousands of small molecules (<1500–2000 Da) present
on a very ample range of concentrations (from <1 nM to>1 μM) and produced by the
genome of the host organism and by the genomes of its microflora, as well as deriving from
exogenous factors like medical treatments [11]. Blood plasma is a primary carrier of small mol-
ecules in the body, the relative concentrations of which reflect the physio-pathological state of
the organism and thus possible tissue lesions and organ dysfunctions. The overall picture is
complemented by alterations in the lipid components [12]. As a consequence, metabolomics
and lipidomics of serum and plasma are increasingly used for successful patient stratification
in various diseases [13–18]. Herein, a strong metabolomic and lipidomic signature of COVID-
19 is revealed via untargeted nuclear magnetic resonance (NMR) spectroscopy of plasma-
EDTA [19,20] from 30 patients compared with age- and sex-matched controls. Moreover, in a
subset of patients, the metabolic effects due to tocilizumab administration were successfully
investigated. This study had no sample-size calculation; the analysis included all patients who
were admitted at the Infective and Tropical Diseases and at the Intensive Care Unit of the Car-
eggi University Hospital, Florence (IT), in the period between March 10 and March 30 2020,
before the rapid decline of hospitalizations for COVID-19.
Results and discussion
We analyzed via 1H NMR spectroscopy the metabolomic and lipidomic profiles of plasma-
EDTA samples obtained from 30 patients affected by COVID-19. SARS-CoV-2 infection was
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confirmed by positive RT-PCR on nasopharyngeal swab specimens. The plasma-EDTA sam-
ples available for the metabolomic analysis were collected between 2–23 days from clinical
onset (mean 9 days). Samples from 30 non COVID-19 subjects, one-to-one matched for age
and sex, were used as control group (CTR). Tocilizumab, a humanized anti-IL-6 receptor
monoclonal antibody, was administered to 8 of the 30 COVID-19 patients enrolled and
another plasma-EDTA sample for each patient was collected after 2–18 days of treatment
(mean 5 days). Demographic and clinical characteristics of enrolled patients are reported in S1
Table. Our analyses considered 21 quantified metabolites and 114 lipoprotein-related parame-
ters [21]. Lipoprotein quantification of plasma samples of two COVID-19 patients (COVID-
19-025 and COVID-19-027) was not possible for the presence of an interfering signal in the
spectra, thus also their respective matched controls (CTR-4 and CTR-7) were removed from
the lipoprotein analyses.
No outliers were identified using principal component analysis (PCA) on the entire popula-
tion, both for metabolite and lipoprotein profiles (S1 Fig).
Plasma metabolite and lipoprotein profiles of COVID-19 patients and CTRs were com-
pared using the Random Forest (RF) algorithm. The eight samples collected post-tocilizumab
treatment are not included in these analyses. The RF model built on metabolite concentrations
shows a significant differential clustering with 91.7% accuracy, 93.3% sensitivity, and 90.0%
specificity (Fig 1A and 1C and S2A and S2 Table). In particular, a panel of 11 metabolites (Fig
1D and S3 Table) displays significant alterations between COVID-19 patients and CTRs. One
of them, giving rise to a detectable multiplet in the region between 7.21–7.30 ppm has not
been assigned and is referred as “unknown”. However, even if this signal is removed from the
statistical model, the discrimination accuracy between COVID-19 patients and CTRs does not
change significantly.
The RF model built on lipoprotein-related parameters shows a significant differential clus-
tering with 87.5% accuracy, 85.7% sensitivity, and 89.3% specificity (Fig 1B and 1C and S2B
and S2 Table). Forty-eight features (Fig 1E and S4 Table) display significant alterations
between COVID-19 patients and CTRs. These results demonstrate that COVID-19 patients
are characterized by higher levels of VLDL particles, and lower levels of Apo A1, Apo A2, cho-
lesterol and free-cholesterol HDL and LDL subfractions. In particular, the subfractions HDL-
3, HDL-4, LDL-4, LDL-5 of cholesterol are the most affected.
Correlations between clinical and metabolomic parameters were calculated and the results
are reported in Fig 2.
Phenylalanine significantly correlates with C-reactive protein (CRP) and interleukin-6.
Inflammation and immune activation impair the conversion of phenylalanine to tyrosine, as
observed in patients suffering from sepsis, cancer, or HIV-1 infection [22–25]; accordingly, we
found higher phenylalanine levels and a trend in lower tyrosine amounts in patients than in
controls. Interestingly, a positive correlation between phenylalanine/tyrosine ratio and high
CRP levels, has been already described by Murr and colleagues [26] in patients affected by cor-
onary artery disease (CAD). These data are in accordance with ours, since SARS-CoV-2 infec-
tion is characterized not only by immune activation and systemic phlogosis, but also by
microvascular endothelial damage and activation of coagulative cascade, as happens in CAD.
Alveolar-arterial O2 gradient anticorrelates with citrate, accordingly the partial pressure of
arterial oxygen and fraction of inspired oxygen (PaO2/FiO2) ratio (known as Horowitz index)
and the ratio between oxygen saturation and fraction of inspired oxygen (SaO2/FiO2) posi-
tively correlates with citrate. This metabolite is known for its anti-oxidative, anti-coagulant
and anti-inflammatory properties [27–29]. SARS-CoV-2 infection can cause lung damage,
leading to ARDS, due not only to alveolar damage but also to diffuse microvascular endothelial
damage and clot activation, mainly driven by pro-inflammatory cytokines, including IL-6
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Fig 1. Metabolomic/lipidomic alterations in COVID-19 patients. (A-B) Proximity plots of the RF model discriminating COVID-19 patients (red dots), and CTR
subjects (green dots) using A) the 21 quantified metabolites and B) the lipoprotein-related parameters. (C) Confusion matrices with predictive accuracy values of each
model. (D) Values of Log2 Fold Change (FC) of quantified metabolites. Grey bars represent p-values< 0.05 after FDR correction. (E) Values of Log2(FC) of lipoprotein-
related parameters significantly different (p-value< 0.05 after FDR correction) between COVID-19 patients and controls. Metabolites/lipoproteins with Log2(FC)
positive/negative values have higher/lower concentration in plasma samples from COVID-19 patients with respect to controls.
https://doi.org/10.1371/journal.ppat.1009243.g001
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[30,31]. The protective role of citrate on endothelial integrity was recently reported by Delle-
piane and colleagues [32]. Moreover, the consumption of citrate and other carboxylates is pro-
moted by hypoxic conditions in red blood cells [33].
Formate shows the inverse pattern of correlation with respect to citrate, and it significantly
correlates also with lactate dehydrogenase and FiO2. Regarding lipoprotein-related parameters
only LDL cholesterol significantly correlates with the SaO2/FiO2 ratio.
Fig 2. Heatmap correlations between clinical and metabolomic parameters. R values are shown as different degree of color intensity (red, positive correlations; blue,
negative correlation). R values are reported in the plot only for statistically significant correlations (p-value< 0.05 after FDR correction).
https://doi.org/10.1371/journal.ppat.1009243.g002
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In line with these observations, metabolites provide an optimal discrimination (accuracy
90.0%, 100.0% sensitivity, 83.3% specificity) between COVID-19 patients treated and non-
treated with invasive ventilation (S3A and S3B Fig), with formate and citrate as the most
important features of the model. Instead, no significant clustering is present in the model cal-
culated with lipoprotein-related parameters (S3C and S3D Fig).
Despite plasma samples of COVID-19 patients are characterized by higher levels of VLDL
and associated triglycerides, we observed a general reduction of HDL and LDL cholesterol-
related parameters. Downregulation of lipids in COVID-19 blood sera has already been
observed [34–37] and it has been hypothesized that lipids (in particular cholesterol and fatty
acids) could play a pivotal role in virus replication and assembly [38,39]. Our data suggest that
only LDL and HDL could be implied in this mechanism.
Accordingly, in a recent study, LDL and HDL levels were inversely correlated to disease
severity and poor prognosis [40]. Furthermore, overproduction of VLDL has been linked with
the processes inducing insulin resistance in COVID-19 patients [35].
We also detected an accumulation of mannose in the plasma of COVID-19 patients and a
significant positive correlation between plasma mannose levels and neutrophils and between
mannose and the neutrophils to lymphocytes ratio. An increment of mannose could be related
to different reasons: it could be associated to its binding to lectin in order to promote comple-
ment activation [34], or it could be linked to insulin resistance. Indeed, plasma mannose levels
are elevated in subjects with insulin resistance independently of obesity [41] and there are
increasing evidences that a bidirectional relationship between COVID-19 and diabetes exists
[42].
The increment of pyruvate and 3-hydroxybutyrate, along with the strong decrement of cit-
rate and free amino acids (alanine, glycine, glutamine, histidine) in plasma of COVID-19
patients can be ascribed to an impairment of the energetic metabolism. Indeed, during inflam-
matory states amino acids can be used to provide energy and materials for the proliferation
and phagocytosis of immune cells. It is important to underline that pyruvate is a metabolite
particularly sensitive to pre-analytical procedures, thus further investigations to confirm its
alteration are needed [43,44].
Among the 30 COVID-19 patients enrolled, 18 patients presented ARDS. Thus, the possi-
bility that ARDS could significantly alter the profile of COVID-19 was examined. The RF
models calculated both on metabolites and lipoprotein-related parameters can only slightly
cluster ARDS patients with respect to the other COVID-19 patients (metabolite model: accu-
racy 76.7%, 88.9% sensitivity, 58.3% specificity; lipoprotein model: accuracy 75.0%, 81.2% sen-
sitivity, 66.7% specificity). These results demonstrate that the metabolomic profile of COVID-
19 patients is mainly dictated by the pathology or by the host response to the virus infection,
rather than by the concomitant presence of ARDS.
Multilevel partial least square discriminant analysis (mPLS-DA) was used to analyze NMR
data of pre- and post-tocilizumab samples in a pairwise multivariate fashion. The mPLS-DA
model built on metabolites shows significant differential clustering, yielding a discrimination
accuracy of 80.3% (Fig 3A). The two pairs of samples collected from patients who died (COVID-
19-020 and COVID-19-021) present the smallest shift within the metabolomic subspace. The
same trend is observed for COVID-19-018 patient who, unfortunately, was transferred to another
hospital and no follow-up and outcome information was available. Univariate analysis enables
the identification of a panel of eight metabolites (Fig 3B–3I and S5 Table) significantly different
(before FDR correction) between pre- and post-tocilizumab patients. The post-treatment levels
of these metabolites partially or completely revert towards the levels of CTR subjects.
The mPLS-DA model built using lipoprotein-related parameters shows a significant dis-
crimination between samples collected pre- and post-tocilizumab treatment (accuracy of
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82.8%) (S4 Fig). Univariate analysis identifies 19 lipoprotein parameters (S6 Table) signifi-
cantly different between pre- and post-tocilizumab treatment. In particular, HDL-1 subfrac-
tions of cholesterol, phospholipids, and Apo A2 showed lower levels at post-treatment,
whereas LDL-5, HDL-4, IDL, VLDL-1, and VLDL-2 of many subfractions are higher at post-
treatment. The general increment of lipoprotein subfractions after treatment confirms the
metabolic reversion and supports the key role of lipids in the metabolism of COVID-19
patients.
In summary, in this study a strong plasma metabolomic and lipidomic signature of Sars-
CoV-2 infection is identified, in agreement with other studies where NMR or mass spectrome-
try have been used to study cohorts of COVID-19 patients from different countries and char-
acterized by different degrees of severity/clinical manifestations [34–37]. Although the two
analytical platforms do not address the same sets of molecules, common metabolic dysfunc-
tions emerge from the comparison of all these studies, which include lipid metabolism, protein
glycosylation and amino acid metabolism. Correlations between clinical parameters and some
metabolites are shown, which include mannose and phenylalanine levels. In addition, here we
found that some molecules, whose levels correlate with alveolar-capillary membrane injury are
Fig 3. Tocilizumab treatment reverts metabolomic/lipidomic alterations in COVID-19 patients. (A) Score plot (of the first two principal
components) and accuracy of the mPLS-DA model discriminating COVID-19 patients at pre- (red dots) and post- (orange dots) tocilizumab
treatment using the 21 quantified metabolites. Patients 18, 20 and 21 are marked with �. (B-I) Boxplots of the statistically significant
metabolites discriminating of pre- (red) and post- (orange) tocilizumab samples, p-values obtained using Wilcoxon signed-rank test are also
reported. Boxplots of controls (green) and the p-values (Wilcoxon-Mann-Whitney test) for the comparison between pre-treatment and CTR
are reported. P-values adjusted for FDR are reported in S5 Table.
https://doi.org/10.1371/journal.ppat.1009243.g003
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affected by mechanical ventilation. Of note, in the case of patients who underwent tocilizumab
treatment, metabolic alterations revert towards those of the control group.
Materials and methods
Ethics statement
The study was approved by the Comitato Etico Regionale- sezione area vasta centro (protocol
16859) and it complies with the 1964 Declaration of Helsinki and its later amendments. Writ-
ten informed consent was obtained from recruited patients.
Patients characteristics
In the period between March 10 and March 30, 2020 we enrolled 30 COVID-19 patients that
were admitted at the Infective and Tropical Diseases Unit and at the Intensive Care Unit of the
Careggi University Hospital, Florence, Italy. All patients were of Caucasian ethnicity. Demo-
graphic and clinical features of the enrolled patients are summarized in S1 Table.
Plasma sample preparation
Plasma samples were collected from all the subjects enrolled in the study, according to stan-
dard procedures [43,44]. Blood samples were collected in ethylene diamine tetra-acetate
(EDTA)-coated blood collection tubes and stored at room temperature. Ficoll, a neutral highly
branched polymer formed by the co-polymerization of sucrose and epichlorohydrin, was used
for blood separation. 14 mL of blood were gently placed in 25 mL tubes containing 9 mL of
Ficoll. Tubes were centrifugated 1500 g for 20 minutes. Plasma was collected and rapidly
stored in a −20˚C freezer pending NMR analysis.
NMR sample preparation, spectra processing and spectral analysis
NMR samples were prepared according to standard procedures [19,20,45]. NMR spectra for
all samples were acquired using a Bruker 600 MHz spectrometer (Bruker BioSpin) operating
at 600.13 MHz proton Larmor frequency and equipped with a 5 mm PATXI 1H-13C-15N and
2H-decoupling probe including a z-axis gradient coil, an automatic tuning-matching (ATM)
and an automatic refrigerated sample changer (SampleJet, Bruker BioSpin). A BTO 2000 ther-
mocouple served for temperature stabilization at the level of approximately 0.1 K of the sam-
ple. Before measurement, to equilibrate temperature at 310 K, samples were kept for at least 5
minutes inside the NMR probe head.
For each plasma sample, two one-dimensional 1H NMR spectra were acquired with water
peak suppression and different pulse sequences that allowed the selective detection of different
molecular components. The spectra were: 1) a standard NOESY using 32 scans, 98,304 data
points, a spectral width of 18,028 Hz, an acquisition time of 2.7 s, a relaxation delay of 4 s and a
mixing time of 0.01 s. This kind of spectrum is made up of signals arising from low molecular
weight molecules (metabolites) and signals arising from macromolecules such as lipoproteins
and lipids; 2) a standard spin echo Carr-Purcell-Meiboom-Gill (CPMG) using 32 scans, 73,728
data points, a spectral width of 12,019 Hz and a relaxation delay of 4 s. This NMR sequence
allows the selective detection of signals arising only from low molecular weight metabolites.
Before applying Fourier transform, free induction decays were multiplied by an exponential
function equivalent to a 0.3 Hz line-broadening factor. Transformed spectra were automati-
cally corrected for phase and baseline distortions and calibrated to the anomeric glucose dou-
bled at δ 5.24 ppm, using TopSpin 3.6.2 (Bruker BioSpin) [19,20].
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Statistical analysis
All data analyses were performed using the “R” statistical environment. Metabolites, whose
peaks in the CPMG spectra were well defined and resolved, were assigned and their concentra-
tions analyzed. The assignment procedure was performed using an 1H NMR spectra library of
pure organic compounds (BBIOREFCODE, Bruker BioSpin), public databases, e.g. Human
Metabolome Database [11], storing reference 1H NMR spectra of metabolites, and using litera-
ture data when available. The spectral regions associated to the 21 assigned metabolites (S7
Table) were integrated using a R script in-house developed. Quantification of 114 lipid main
fractions and subfractions was performed using the Bruker IVDr platform [21].
Both metabolites and lipoprotein-related parameters were analyzed via multivariate analy-
sis. Unsupervised Principal Component Analysis (PCA) was used as first exploratory analysis
to obtain a preliminary data outlook (i.e. cluster detection and screening for outliers). The
Random Forest (RF) algorithm [46] was used for classification in the comparison between
COVID-19 patients and CTR. RF is a classification algorithm that uses an ensemble of
unpruned decision trees (forest), each of which is built on a bootstrap sample of the training
data using a randomly selected subset of variables (metabolites or lipoprotein-related parame-
ters) [47,48]. The percentage of trees in the forest that assign one sample to a specific class can
be inferred as a probability of belonging to a given class [13]. In our case, each tree was used to
predict whether a sample represents a COVID-19 patient or a CTR subject. Because the out-
of-bag (OOB) observations were not used in the fitting of the trees, the OOB estimates are
cross-validated, accuracy estimates, and represent an unbiased estimation of the generalization
error [46]. Accuracy, sensitivity, and specificity of all calculated models were assessed accord-
ing to the standard definitions. For all calculations, the R package ‘Random Forest’ [46] was
used to grow a forest of 1000 trees, using the default settings.
Pairwise comparisons between pre- and post-treatment samples were performed using
multilevel Partial Least Square Discriminant Analysis (mPLS-DA) and results validated using
a Monte Carlo Cross-Validation scheme (MCCV, script in house developed): each dataset was
randomly divided by 1000 times into a training set (80% of the data) which was used to build
the model and a test set (20% of the data) which was used to test the integrity of the model.
Accuracy, sensitivity, and specificity of all calculated models were assessed according to the
standard definitions.
On the biological assumption that metabolite and lipoprotein concentrations are not nor-
mally distributed, non-parametric tests were used for the univariate analysis. Wilcoxon-
Mann-Whitney test was used to infer differences between the metabolite/lipid levels in the
comparison between COVID-19 patients and CTR. Instead for pairwise comparison between
pre- and post-treatment samples the Wilcoxon signed-rank test was utilized [49]. P-values
were adjusted for multiple testing using the false discovery rate (FDR) procedure with Benja-
mini-Hochberg [50] correction at α = 0.05. The effect size (Ef) was also calculated [51] to aid
in the identification of the meaningful signals giving an estimation of the magnitude of the
separation between the different groups. The magnitude is assessed using the thresholds pro-
vided in Romano et al. [52], i.e. |Ef|< 0.147 “negligible”, |Ef|< 0.33 “small”, |Ef|< 0.474
“medium”, otherwise “large”. Pearson correlations, adjusted for FDR using BH methods, were
also calculated.
Supporting information
S1 Fig. PCA analysis. Score plots (PC1 vs. PC2) of the unsupervised PCA model of A) 21
quantified metabolites, B) lipoprotein-related parameters; COVID-19 patients (red dots); CTR
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subjects (green dots).
(TIF)
S2 Fig. Metabolomic/lipidomic alterations in COVID-19 patients. Variable importance
plots of the Random Forest models discriminating COVID-19 patients and control subjects.
A) 21 quantified metabolites, B) lipoprotein-related parameters.
(TIF)
S3 Fig. Alterations induced by invasive ventilation in COVID-19 patients. Proximity plot
(of the first two principal components) and accuracy of the Random Forest model discriminat-
ing COVID-19 patients treated (blue dots) and non-treated (sea green dots) with invasive ven-
tilation using metabolites (A) and lipoprotein-related parameters (C). Variable importance
plots of the two Random Forest models: B) 21 quantified metabolites, D) lipoprotein-related
parameters.
(TIF)
S4 Fig. Alterations in lipoprotein profile induced by Tocilizumab treatment. A) Score plot
(of the first two principal components) and accuracy of the mPLS-DA model discriminating
COVID-19 patients pre- (red dots) and post- (orange dots) tocilizumab treatment using the
lipoprotein-related parameters.
(TIF)
S1 Table. Demographic and clinical characteristics of COVID-19 patients. ACF denotes
acute cardiac failure, AI autoimmune disease, AKI acute kidney injury, ARDS acute respira-
tory distress syndrome, CKD chronic kidney disease, CVD cardiovascular disease, D deceased,
DBT type 2 diabetes, DH discharged home, DYS dyslipidemia, H hypertension, K cancer,
LTFU lost to follow-up.
(XLSX)
S2 Table. Metabolomic/lipidomic alterations in COVID-19 patients: multivariate analysis.
Random Forest scores of the model discriminating COVID-19 patients and controls using the
21 quantified metabolites and lipoprotein-related parameters. P: predicted class; S. numeric
score (controls: 0<S< 0.5; COVID-19 patients: 0.5< S< 1).
(XLSX)
S3 Table. Metabolomic alterations in COVID-19 patients: univariate analysis. Univariate
analysis of the 21 quantified metabolites for the comparison between COVID-19 patients and
control subjects. The median and MAD of each metabolite in the two groups are reported. The
p-value of the univariate Wilcoxon-Mann-Whitney test together with the p-value calculated
after false discovery rate correction and the effect size, using the Cliff’s delta formulation, were
also reported for each metabolite.
(XLSX)
S4 Table. Lipidomic alterations in COVID-19 patients: univariate analysis. Univariate anal-
ysis of the lipoprotein-related parameters for the comparison between COVID-19 patients and
control subjects. The median and MAD of each parameter in the two groups are reported. The
p-value of the univariate Wilcoxon-Mann-Whitney test together with the p-value calculated
after false discovery rate correction and the effect size, using the Cliff’s delta formulation, were
also reported for each parameter.
(XLSX)
S5 Table. Metabolomic alterations induced by Tocilizumab treatment: univariate analysis.
Univariate analysis of the 21 quantified metabolites for the comparison between COVID-19
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patients before and after tocilizumab treatment. The p-value of the univariate Wilcoxon-
Signed-Rack test together with the p-value calculated after false discovery rate correction and
the effect size were reported for each metabolite.
(XLSX)
S6 Table. Lipidomic alterations induced by Tocilizumab treatment: univariate analysis.
Univariate analysis of the lipoprotein-related parameters for the comparison between
COVID-19 patients before and after tocilizumab treatment. The p-value of the univariate Wil-
coxon-Signed-Rack test together with the p-value calculated after false discovery rate correc-
tion and the effect size were reported for each parameter.
(XLSX)
S7 Table. List of the metabolites assigned and analyzed in plasma samples. For each metab-
olite, the chemical shift of the signal used for the analysis and the corresponding multiplicity
are provided; d. s = singlet; d = doublet; t = triplet; dd = doublet of doublets; m = multiplet.
The Human Metabolome Database (HMDB) compound ID of each metabolite is reported.
(XLSX)
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